+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Viral Vectors Market - Global Forecast 2026-2032- Product Image
Viral Vectors Market - Global Forecast 2026-2032- Product Image
Sale

Viral Vectors Market - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • July 2026
  • Region: Global
  • 360iResearch™
  • ID: 5666371
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Viral Vectors Market is projected to reach USD 4.92 Billion in 2026. It is expected to continue growing at a CAGR of 14.96%, reaching USD 11.40 Billion by 2032.

Viral vectors are central to modern cell and gene therapy, vaccine development, oncology research, and in vivo genetic medicine. These engineered delivery systems, including adeno-associated virus vectors, lentiviral vectors, adenoviral vectors, retroviral vectors, and herpes simplex virus vectors, are used to transfer genetic material into target cells for therapeutic or research purposes. Demand is being shaped by the growing clinical use of gene therapies, expanding CAR-T and immune-cell therapy pipelines, and continued investment in advanced biomanufacturing. Regulatory agencies have issued increasingly detailed guidance on vector characterization, potency assays, replication-competent virus testing, biodistribution, shedding, and long-term follow-up, reinforcing the need for robust quality systems. The viral vectors landscape is therefore moving beyond discovery-stage enablement toward industrialized, compliant, and scalable manufacturing models that support translational research, clinical trials, and approved advanced therapies.

Transformative Shifts in Viral Vector Development and Manufacturing

The viral vectors sector is undergoing a structural shift from bespoke, small-batch production toward standardized, platform-based manufacturing. AAV vectors remain widely used for in vivo gene delivery because of their tissue tropism and relatively favorable safety profile, while lentiviral vectors continue to be important for ex vivo cell therapies due to stable genomic integration in dividing and non-dividing cells. At the same time, adenoviral and other vector systems continue to support vaccine platforms, cancer immunotherapy, and gene-editing delivery research. Key transformation areas include producer cell line development, suspension-based culture systems, serum-free media, improved transfection technologies, stable packaging systems, and closed, automated processing. Analytical complexity is also rising, with greater attention to full-to-empty capsid ratios, vector genome integrity, residual host cell DNA, adventitious agent testing, potency, and comparability after process changes. These shifts are being accelerated by regulatory scrutiny, supply-chain resilience priorities, and the need to reduce batch failure risk while improving reproducibility across clinical and commercial production environments.

Cumulative Impact of Artificial Intelligence on Viral Vectors

Artificial intelligence is beginning to influence viral vector discovery, process development, quality control, and regulatory documentation. Machine learning models can support capsid engineering by analyzing sequence-function relationships, immunogenicity signals, tissue tropism patterns, and manufacturability constraints. In upstream development, AI-enabled design of experiments can help optimize transfection conditions, cell culture parameters, media composition, and harvest timing. In downstream processing, advanced analytics can improve chromatography optimization, impurity prediction, and yield consistency. AI is also being applied to image analysis, digital batch records, anomaly detection, and predictive maintenance across GMP facilities. However, its impact depends on high-quality datasets, validated models, transparent governance, and alignment with regulatory expectations for computerized systems and data integrity. The strongest near-term value is likely to come from combining AI with high-throughput screening, process analytical technology, and digital quality management to shorten development cycles while strengthening evidence generation for viral vector products.

Key Regional Insights Across the Viral Vectors Ecosystem

Asia-Pacific is strengthening its role in viral vector research and manufacturing through expanding biotechnology infrastructure, government-backed life sciences programs, and rising clinical trial activity in China, Japan, South Korea, India, Australia, and Singapore. The region benefits from large patient populations, growing academic translational research, regenerative medicine policies, and increasing investment in GMP-compliant cell and gene therapy facilities. Europe has a deeply established advanced therapy environment, supported by cross-border research programs, centralized regulatory assessment, hospital-based innovation, and strong activity in Germany, France, the United Kingdom, Italy, and Spain. The European regulatory framework for advanced therapy medicinal products supports structured evaluation of gene therapies and viral vector-enabled products, with sustained emphasis on quality, safety, pharmacovigilance, and long-term patient monitoring. North America remains a highly active hub for viral vector innovation, supported by a mature biotechnology ecosystem, specialized contract manufacturing capacity, academic medical centers, and defined regulatory pathways for advanced therapies. The United States drives much of the region’s momentum through gene therapy approvals, clinical development, and manufacturing specialization, while Canada contributes strong research networks and cell therapy capabilities. Latin America is gradually building capacity, with Brazil and Mexico advancing biomedical research, clinical trial participation, vaccine capabilities, and regulatory modernization, although access, infrastructure, and specialized manufacturing remain uneven. Africa remains an emerging geography for viral vector applications, with opportunities linked to vaccine research, infectious disease preparedness, genomics capacity, and international research partnerships, though local manufacturing, workforce development, and cold-chain infrastructure remain key development priorities. The Middle East is investing in precision medicine, genomics, and specialized healthcare infrastructure, particularly in Gulf states that are developing biotechnology clusters, national genome programs, and advanced clinical care models that may support future viral vector-enabled therapy access.

Key Group Insights Shaping Viral Vector Adoption

NATO member countries overlap significantly with leading biopharmaceutical markets in North America and Europe, where supply-chain security, biosecurity, pandemic preparedness, and resilient manufacturing infrastructure are increasingly linked to national health strategy. The G7 remains influential in viral vector innovation because its members host advanced regulatory agencies, academic research institutions, GMP manufacturing capacity, and established health technology assessment and reimbursement discussions for cell and gene therapies. BRICS countries are strategically important because they combine large patient populations, growing domestic biotechnology ambitions, and public-sector interest in healthcare sovereignty; China and India are particularly active in manufacturing expansion and clinical research, while Brazil, Russia, and South Africa contribute regional scientific, vaccine, and healthcare access perspectives. The European Union provides one of the most structured regulatory and research environments for viral vectors through advanced therapy medicinal product frameworks, cross-country research funding, pharmacovigilance systems, and harmonized quality expectations, although implementation can vary by member state. ASEAN is becoming increasingly relevant to viral vector and advanced therapy development as Singapore leads in biomedical manufacturing and translational research, while Malaysia, Thailand, Indonesia, Vietnam, and the Philippines expand clinical research capacity and biopharmaceutical capabilities. The GCC is emphasizing genomics, precision medicine, and high-acuity healthcare investment, creating opportunities for specialized therapy access, clinical collaborations, rare disease programs, and future regional biomanufacturing foundations.

Key Country Insights in Viral Vector Research and Manufacturing

China is rapidly expanding viral vector manufacturing, gene therapy clinical activity, and domestic biopharmaceutical innovation, supported by substantial investment in life sciences infrastructure and a large clinical research base. The United States is a leading center for viral vector development, supported by a dense network of academic research institutions, clinical trial sites, regulatory experience, and specialized manufacturing facilities. Japan has a well-established regenerative medicine and gene therapy regulatory environment and strong academic-industry collaboration, while India is developing capabilities in biologics, vaccines, contract development, and clinical research, with increasing interest in gene therapy for rare and inherited diseases. Germany is notable for engineering depth, bioprocessing expertise, and advanced therapy research, while the United Kingdom maintains strong capabilities in genomics, viral vector manufacturing, and clinical translation. Australia supports early-phase clinical development, translational medicine, and high-quality biomedical research infrastructure. France supports gene therapy and vaccine innovation through national research networks, public research institutions, and advanced clinical centers. South Korea is building a competitive advanced biomanufacturing ecosystem, with strengths in biologics production, cell therapy development, and government-backed biotechnology initiatives. Italy and Spain continue to advance hospital-based cell and gene therapy programs, academic clinical research, and advanced therapy manufacturing know-how. Canada contributes strong translational science, cell therapy research, and public-private collaboration, while Russia maintains scientific capabilities in virology, vaccine platforms, and biomedical research despite geopolitical and supply-chain constraints. Brazil is Latin America’s most prominent biotechnology market, with public health research institutions, vaccine expertise, and increasing attention to advanced therapeutic platforms, and Mexico is expanding clinical research and biopharmaceutical capabilities with growing interest in advanced therapies.

Actionable Recommendations for Viral Vector Industry Leaders

Industry leaders should prioritize platform manufacturing strategies that can support multiple vector types while maintaining clear product-specific controls. Investments in scalable upstream systems, closed processing, automation, and validated analytical methods can reduce variability and support regulatory confidence. Organizations should strengthen capabilities in vector characterization, potency assay development, sterility assurance, residual impurity testing, adventitious agent control, and comparability protocols, as these areas are critical for clinical progression and lifecycle management. Supply-chain resilience should include dual sourcing of critical raw materials, qualified plasmid DNA supply, robust cold-chain logistics, and contingency planning for single-use systems, specialized reagents, and analytical reference standards. Leaders should also integrate digital quality systems, electronic batch records, and AI-assisted process monitoring with strong data governance, cybersecurity controls, and validation procedures. Partnerships with academic centers, hospitals, regulators, and specialized manufacturing organizations can accelerate translation, but technology transfer plans must be detailed, documented, and risk-based. Finally, teams should engage early with regulators on vector design, biodistribution, shedding, immunogenicity, insertional mutagenesis risk where relevant, and long-term follow-up requirements to reduce development uncertainty.

Research Methodology for Viral Vector Insights

This executive summary is developed through a structured secondary research approach using publicly available and verifiable sources, including regulatory guidance documents, peer-reviewed scientific literature, clinical trial registries, health agency communications, advanced therapy policy publications, patent and technology trend reviews, and official government or institutional biotechnology initiatives. The analysis emphasizes validated developments in viral vector science, manufacturing practices, quality control, regional ecosystem maturity, and regulatory direction. Information is cross-checked across multiple credible source categories to reduce dependence on single-source interpretation and to align insights with established evidence from regulatory, scientific, and public health sources. The methodology excludes market sizing, market share, revenue estimation, and forecasting, focusing instead on evidence-based qualitative assessment of technology adoption, regional capabilities, manufacturing evolution, and strategic implications for stakeholders in gene therapy, cell therapy, vaccines, and advanced biologics.

Conclusion on the Future of Viral Vectors

Viral vectors remain a foundational technology for the next generation of genetic medicines, advanced cell therapies, cancer immunotherapies, and vaccine platforms. The landscape is being reshaped by scalable manufacturing, improved analytics, regulatory maturity, and the selective use of artificial intelligence in discovery and process optimization. Regional ecosystems differ in infrastructure, regulatory experience, clinical capacity, and manufacturing readiness, but global momentum is clear as more countries invest in biotechnology, genomics, precision medicine, and advanced therapy capabilities. Success in this field will depend on reliable vector design, reproducible GMP production, validated quality controls, resilient supply chains, and early regulatory alignment. Organizations that combine scientific innovation with operational discipline will be best positioned to advance safe, effective, and accessible viral vector-enabled therapies.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Viral Vectors Market, by Vector Type
7.1. Introduction
7.2. Adeno Associated Virus
7.2.1. AAV2
7.2.2. AAV8
7.2.3. AAV9
7.3. Adenovirus
7.4. Lentivirus
7.5. Retrovirus
8. Viral Vectors Market, by Therapeutic Area
8.1. Introduction
8.2. Cardiovascular Disorders
8.2.1. Coronary
8.2.2. Peripheral Vascular
8.3. Infectious Disease
8.3.1. Bacterial
8.3.2. Viral
8.4. Neurological Disorders
8.4.1. Neurodegenerative
8.4.2. Neurodevelopmental
8.5. Oncology
8.5.1. Hematological
8.5.2. Solid Tumor
8.6. Rare Diseases
9. Viral Vectors Market, by Production Stage
9.1. Introduction
9.2. Downstream
9.2.1. Filtration
9.2.2. Formulation
9.2.3. Purification
9.2.3.1. Chromatography
9.2.3.2. Ultracentrifugation
9.3. Upstream
9.3.1. Cell Expansion
9.3.2. Harvesting
9.3.3. Transfection
10. Viral Vectors Market, by Application
10.1. Introduction
10.2. Cell Therapy
10.2.1. Car T
10.2.2. Dendritic
10.2.3. TCR T
10.3. Gene Therapy
10.3.1. Ex Vivo
10.3.2. In Vivo
10.4. Research
10.4.1. Basic Research
10.4.2. Preclinical Research
10.5. Vaccine
10.5.1. Prophylactic
10.5.2. Therapeutic
11. Viral Vectors Market, by End User
11.1. Introduction
11.2. Biopharma Companies
11.3. Hospitals And Clinics
11.4. Research Institutes
12. Viral Vectors Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Viral Vectors Market, by Group
13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC
14. Viral Vectors Market, by Country
14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. ABL Inc.
16.2. Batavia Biosciences B.V. by CJ Cheiljedang
16.3. Biovian Oy
16.4. Charles River Laboratories International, Inc.
16.5. Creative Biogene
16.6. Danaher Corporation
16.7. F. Hoffmann-La Roche Ltd.
16.8. FinVector Oy
16.9. FUJIFILM Holdings Corporation
16.10. GE HealthCare Technologies, Inc.
16.11. Genezen Laboratories, Inc.
16.12. Kaneka Eurogentec S.A.
16.13. Lonza Group Ltd.
16.14. Merck KGaA
16.15. Miltenyi Biotec GmbH
16.16. Novartis AG
16.17. Oxford Biomedica PLC
16.18. PackGene Biotech lnc.
16.19. Sanofi SA
16.20. Sirion-Biotech GmbH
16.21. Takara Bio Inc.
16.22. Thermo Fisher Scientific Inc.
16.23. uniQure N.V.
16.24. VGXI, Inc. by GeneOne Life Science
16.25. Waisman Biomanufacturing
16.26. Wuxi AppTec Co., Ltd.
List of Figures
FIGURE 1. GLOBAL VIRAL VECTORS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL VIRAL VECTORS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL VIRAL VECTORS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL VIRAL VECTORS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL VIRAL VECTORS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 9. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL VIRAL VECTORS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL VIRAL VECTORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL VIRAL VECTORS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL VIRAL VECTORS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL VIRAL VECTORS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL VIRAL VECTORS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ADENO ASSOCIATED VIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ADENO ASSOCIATED VIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ADENO ASSOCIATED VIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL AAV2 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL AAV2 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL AAV2 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL AAV8 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL AAV8 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL AAV8 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL AAV9 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL AAV9 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL AAV9 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ADENOVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ADENOVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ADENOVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL LENTIVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL LENTIVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL LENTIVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL RETROVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL RETROVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL RETROVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CARDIOVASCULAR DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CARDIOVASCULAR DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CARDIOVASCULAR DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CORONARY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CORONARY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CORONARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PERIPHERAL VASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PERIPHERAL VASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PERIPHERAL VASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL BACTERIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL BACTERIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL BACTERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL VIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL VIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL VIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL NEURODEGENERATIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL NEURODEGENERATIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NEURODEGENERATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NEURODEVELOPMENTAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NEURODEVELOPMENTAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL NEURODEVELOPMENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL HEMATOLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL HEMATOLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL HEMATOLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL SOLID TUMOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL SOLID TUMOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL SOLID TUMOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL RARE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL RARE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL RARE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL DOWNSTREAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL DOWNSTREAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL DOWNSTREAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL FILTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL FILTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL FILTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL FORMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL FORMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL FORMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL PURIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL PURIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL PURIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL CHROMATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL CHROMATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL CHROMATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ULTRACENTRIFUGATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ULTRACENTRIFUGATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ULTRACENTRIFUGATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL UPSTREAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL UPSTREAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL UPSTREAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL CELL EXPANSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL CELL EXPANSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL CELL EXPANSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL HARVESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL HARVESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL HARVESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL TRANSFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL TRANSFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL TRANSFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL CAR T MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL CAR T MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL CAR T MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL DENDRITIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL DENDRITIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL DENDRITIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL TCR T MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL TCR T MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL TCR T MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL EX VIVO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL EX VIVO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL EX VIVO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL IN VIVO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL IN VIVO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL IN VIVO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL BASIC RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL BASIC RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL BASIC RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL PRECLINICAL RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL PRECLINICAL RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL PRECLINICAL RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL PROPHYLACTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL PROPHYLACTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL PROPHYLACTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL THERAPEUTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL THERAPEUTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL BIOPHARMA COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL BIOPHARMA COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL BIOPHARMA COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 161. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. EUROPE VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 166. EUROPE VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 167. EUROPE VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 168. EUROPE VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 169. EUROPE VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 170. EUROPE VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 171. EUROPE VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 172. EUROPE VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 173. EUROPE VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 174. EUROPE VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 175. EUROPE VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 176. EUROPE VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 177. EUROPE VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 178. EUROPE VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 179. EUROPE VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 180. EUROPE VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 181. EUROPE VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 182. EUROPE VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 183. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 184. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 185. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 186. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 187. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 188. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 189. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 190. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 191. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 192. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 193. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 194. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 195. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 196. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 197. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 198. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 199. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 200. NORTH AMERICA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 201. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 202. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 203. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 204. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 205. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 206. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 207. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 208. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 209. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 210. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 211. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 212. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 213. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 214. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 215. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 216. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 217. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 218. LATIN AMERICA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 219. AFRICA VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 220. AFRICA VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 221. AFRICA VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 222. AFRICA VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 223. AFRICA VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 224. AFRICA VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 225. AFRICA VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 226. AFRICA VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 227. AFRICA VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 228. AFRICA VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 229. AFRICA VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 230. AFRICA VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 231. AFRICA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 232. AFRICA VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 233. AFRICA VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 234. AFRICA VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 235. AFRICA VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 236. AFRICA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 237. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 238. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 239. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 240. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 241. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 242. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 243. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 244. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 245. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 246. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 247. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 248. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 249. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 250. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 251. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 252. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 253. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 254. MIDDLE EAST VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 255. GLOBAL VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 256. NATO VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 257. NATO VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 258. NATO VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 259. NATO VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 260. NATO VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 261. NATO VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 262. NATO VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 263. NATO VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 264. NATO VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 265. NATO VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 266. NATO VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 267. NATO VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 268. NATO VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 269. NATO VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 270. NATO VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 271. NATO VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 272. NATO VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 273. NATO VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 274. G7 VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 275. G7 VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 276. G7 VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 277. G7 VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 278. G7 VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 279. G7 VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 280. G7 VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 281. G7 VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 282. G7 VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 283. G7 VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 284. G7 VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 285. G7 VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 286. G7 VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 287. G7 VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 288. G7 VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 289. G7 VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 290. G7 VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 291. G7 VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 292. BRICS VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 293. BRICS VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 294. BRICS VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 295. BRICS VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 296. BRICS VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 297. BRICS VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 298. BRICS VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 299. BRICS VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 300. BRICS VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 301. BRICS VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 302. BRICS VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 303. BRICS VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 304. BRICS VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 305. BRICS VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 306. BRICS VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 307. BRICS VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 308. BRICS VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 309. BRICS VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 310. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 311. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 312. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 313. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 314. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 315. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 316. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 317. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 318. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 319. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 320. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 321. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 322. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 323. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 324. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 325. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 326. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 327. EUROPEAN UNION VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 328. ASEAN VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 329. ASEAN VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 330. ASEAN VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 331. ASEAN VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 332. ASEAN VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 333. ASEAN VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 334. ASEAN VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 335. ASEAN VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 336. ASEAN VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 337. ASEAN VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 338. ASEAN VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 339. ASEAN VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 340. ASEAN VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 341. ASEAN VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 342. ASEAN VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 343. ASEAN VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 344. ASEAN VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 345. ASEAN VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 346. GCC VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 347. GCC VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 348. GCC VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 349. GCC VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 350. GCC VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 351. GCC VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 352. GCC VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 353. GCC VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 354. GCC VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 355. GCC VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 356. GCC VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 357. GCC VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 358. GCC VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 359. GCC VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 360. GCC VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 361. GCC VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 362. GCC VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 363. GCC VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 364. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 365. CHINA VIRAL VECTORS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 366. CHINA VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 367. CHINA VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 368. CHINA VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 369. CHINA VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)
TABLE 370. CHINA VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
TABLE 371. CHINA VIRAL VECTORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 372. CHINA VIRAL VECTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
TABLE 373. CHINA VIRAL VECTORS MARKET SIZE, BY PRODUCTION STAGE, 2018-2032 (USD MILLION)
TABLE 374. CHINA VIRAL VECTORS MARKET SIZE, BY DOWNSTREAM, 2018-2032 (USD MILLION)
TABLE 375. CHINA VIRAL VECTORS MARKET SIZE, BY PURIFICATION, 2018-2032 (USD MILLION)
TABLE 376. CHINA VIRAL VECTORS MARKET SIZE, BY UPSTREAM, 2018-2032 (USD MILLION)
TABLE 377. CHINA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 378. CHINA VIRAL VECTORS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 379. CHINA VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
TABLE 380. CHINA VIRAL VECTORS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
TABLE 381. CHINA VIRAL VECTORS MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
TABLE 382. CHINA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 383. UNITED STATES VIRAL VECTORS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 384. UNITED STATES VIRAL VECTORS MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 385. UNITED STATES VIRAL VECTORS MARKET SIZE, BY ADENO ASSOCIATED VIRUS, 2018-2032 (USD MILLION)
TABLE 386. UNITED STATES VIRAL VECTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 387. UNITED STATES VIRAL VECTORS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2032 (USD MILLION)

Companies Mentioned

  • ABL Inc.
  • Batavia Biosciences B.V. by CJ Cheiljedang
  • Biovian Oy
  • Charles River Laboratories International, Inc.
  • Creative Biogene
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • FinVector Oy
  • FUJIFILM Holdings Corporation
  • GE HealthCare Technologies, Inc.
  • Genezen Laboratories, Inc.
  • Kaneka Eurogentec S.A.
  • Lonza Group Ltd.
  • Merck KGaA
  • Miltenyi Biotec GmbH
  • Novartis AG
  • Oxford Biomedica PLC
  • PackGene Biotech lnc.
  • Sanofi SA
  • Sirion-Biotech GmbH
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • uniQure N.V.
  • VGXI, Inc. by GeneOne Life Science
  • Waisman Biomanufacturing
  • Wuxi AppTec Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages184
PublishedJuly 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 4.92 Billion
Forecasted Market Value ( USD ) by 2032 $ 11.4 Billion
Compound Annual Growth Rate14.9%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Viral Vector & Plasmid DNA Manufacturing Market by Product Type, Service Type, Workflow Stage, Production Platform, Bioprocess Mode, Source, Application, End User, Disease Area - Global Forecast 2026-2032 - Product Image

Viral Vector & Plasmid DNA Manufacturing Market by Product Type, Service Type, Workflow Stage, Production Platform, Bioprocess Mode, Source, Application, End User, Disease Area - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Viral Vector Manufacturing Market - Global Forecast 2026-2032 - Product Image

Viral Vector Manufacturing Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Viral Vector Market Size, Share & Trends Analysis Report by Vector Type, Application, End Use, Region, and Segment Forecasts, 2026-2033 - Product Image

Viral Vector Market Size, Share & Trends Analysis Report by Vector Type, Application, End Use, Region, and Segment Forecasts, 2026-2033

  • Report
  • 180 Pages
  • Global
From
Viral Vector Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Viral Vector Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 299 Pages
  • Global
From
Viral Vector Manufacturing - Global Strategic Business Report - Product Image

Viral Vector Manufacturing - Global Strategic Business Report

  • Report
  • 402 Pages
  • Global
From

About the Viral Vector Market

The Viral Vector market is a subset of the biotechnology industry that focuses on the development and production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, genetic disorders, and infectious diseases. Viral vectors are produced through a variety of methods, including recombinant DNA technology, synthetic biology, and cell-based systems. The production of viral vectors requires specialized equipment and expertise, making it a highly specialized field. The Viral Vector market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Novartis, Merck, Pfizer, AstraZeneca, and Sanofi. Additionally, there are a number of smaller companies that specialize in the production of viral vectors, such as Viralgen, Oxford BioMedica, and Vigene Biosciences. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.